← All trials
NCT05579730
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2022
- Primary completion
- Mar 28, 2023
- Completion date
- Mar 28, 2023
- First posted
- Oct 14, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 300
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bausch & LombLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.